PHAXIAM Therapeutics (PHXM) News Today $3.10 0.00 (0.00%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period PHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"November 18, 2024 | globenewswire.comPhaxiam Therapeutics S.A.: PHAXIAM Reports Third-Quarter 2024 Financial InformationNovember 13, 2024 | finanznachrichten.dePHAXIAM Reports Third-Quarter 2024 Financial InformationNovember 13, 2024 | globenewswire.comPHAXIAM Therapeutics S.A. (PHXM.PA)November 6, 2024 | finance.yahoo.comPHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.November 4, 2024 | globenewswire.comPHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 studyOctober 9, 2024 | finance.yahoo.comPhaxiam Therapeutics S.A.: PHAXIAM Provides Business and Financial Update For the First Half of 2024September 26, 2024 | finanznachrichten.dePHAXIAM Provides Business and Financial Update For the First Half of 2024September 25, 2024 | globenewswire.comResults of the Combined General Meeting of 28 June 2024June 28, 2024 | globenewswire.comPHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024June 7, 2024 | globenewswire.comPhaxiam Therapeutics S.A.: PHAXIAM provides Business and Financial Update for the First Quarter of 2024May 15, 2024 | finanznachrichten.dePHAXIAM provides Business and Financial Update for the First Quarter of 2024May 15, 2024 | globenewswire.comPhaxiam enrols first patient in endocarditis infection studyApril 15, 2024 | msn.comPHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureusApril 15, 2024 | globenewswire.comPhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)April 5, 2024 | finanznachrichten.dePHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)April 5, 2024 | globenewswire.comONCT Oncternal Therapeutics, Inc.March 23, 2024 | seekingalpha.comPHAXIAM Announces 2023 Full-Year Results and Provides Business UpdateMarch 20, 2024 | globenewswire.comPhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock MarketMarch 11, 2024 | finanznachrichten.dePhaxiam Therapeutics Says Delisting Of ADSs From Nasdaq EffectiveMarch 11, 2024 | markets.businessinsider.comPHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock MarketMarch 11, 2024 | globenewswire.comMonthly information related to total number of voting rights and shares composing the share capital - February 29, 2024March 5, 2024 | finance.yahoo.comTrading was temporarily halted for "PHXM" at 09:02 AM with a stated reason of "LULD pause."February 21, 2024 | marketbeat.comTrading was temporarily halted for "PHXM" at 04:02 PM with a stated reason of "News pending."February 20, 2024 | marketbeat.comPHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital MarketFebruary 20, 2024 | globenewswire.comMonthly information related to total number of voting rights and shares composing the share capital - January 31, 2024February 7, 2024 | finance.yahoo.comPhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024January 19, 2024 | finanznachrichten.dePHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024January 18, 2024 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital - December 31, 2023January 3, 2024 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital - November 30, 2023December 6, 2023 | finance.yahoo.comPhaxiam Therapeutics Share Price (PHXM.PA)November 28, 2023 | lse.co.ukPhaxiam Therapeutics S.A.: PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023November 15, 2023 | finanznachrichten.dePHAXIAM Therapeutics SA ADR PHXMNovember 14, 2023 | morningstar.comPHAXIAM Provides Business and Financial Update for the Third Quarter of 2023November 14, 2023 | finance.yahoo.comTrading was temporarily halted for "PHXM" at 10:11 AM with a stated reason of "LULD pause."November 14, 2023 | marketbeat.comPHAXIAM Therapeutics SA ADRNovember 11, 2023 | morningstar.comMonthly information related to total number of voting rights and shares composing the share capital _ October 31, 2023November 7, 2023 | finance.yahoo.comPhaxiam Therapeutics SA DRC (PHXM)October 29, 2023 | investing.comPHAXIAM Therapeutics obtains authorizations to launch its phase 1 study in endocarditis infections caused by Staphylococcus aureusOctober 24, 2023 | finance.yahoo.comPhaxiam Therapeutics S.A.: TP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a "Buy" recommendationOctober 23, 2023 | finanznachrichten.deTP ICAP Midcap initiates coverage of PHAXIAM Therapeutics with a “Buy” recommendationOctober 23, 2023 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital _September 30, 2023October 23, 2023 | finance.yahoo.comPHAXIAM Therapeutics announces high coverage performance of its two anti-Staphylococcus aureus phages over clinical strainsOctober 9, 2023 | markets.businessinsider.comPHAXIAM Receives Compliance Notice from NasdaqOctober 4, 2023 | finance.yahoo.comPhaxiam Therapeutics S.A.: PHAXIAM Therapeutics and Vetophage Announce Strategic Research CollaborationOctober 3, 2023 | finanznachrichten.dePHAXIAM Therapeutics and Vetophage Announce Strategic Research CollaborationOctober 3, 2023 | finance.yahoo.comPHAXIAM Therapeutics SA (PHXM)September 22, 2023 | investing.comPHAXIAM Provides Business and Financial Update For the First Half of 2023September 22, 2023 | markets.businessinsider.comPHAXIAM Therapeutics S.A. (PHXM)September 21, 2023 | finance.yahoo.comTrading was temporarily halted for "PHXM" at 09:09 AM with a stated reason of "LULD pause." Trading set to resume at 09:09 AM. September 19, 2023 | marketbeat.com Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Email Address Ever heard of this 8-day bitcoin profit window? (Ad)Did you know Bitcoin almost always soars higher during an 8-Day Profit Window? Most people have no clue… But for over a year now, some of our top students have had the chance to cash in with some incredible gains during this 8-day window. It’s coming up quick. PHXM Media Mentions By Week PHXM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PHXM News Sentiment▼0.000.49▲Average Medical News Sentiment PHXM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PHXM Articles This Week▼10▲PHXM Articles Average Week Get PHAXIAM Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PHXM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Reviva Pharmaceuticals News Today Rallybio News Today Barinthus Biotherapeutics News Today Anebulo Pharmaceuticals News Today CEL-SCI News Today Lumos Pharma News Today OS Therapies News Today CERo Therapeutics News Today OKYO Pharma News Today RAPT Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PHXM) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share PHAXIAM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
